Revenue from contracts with customers (Tables)

12 Months Ended

Dec. 31, 2024

Summary of disaggregates revenues by major revenue streams

The following table disaggregates Teva’s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 19.

In conjunction with a recent shift in executive management responsibilities and in alignment with Teva’s Pivot to Growth strategy, Teva decided that Canada is no longer included as part of Teva’s North America segment as of January 1, 2024. From that date Canada is reported as part of the Company’s International Markets segment and Teva’s North America segment has been renamed the United States segment. Teva aligned its internal financial and segment reporting and its reporting units in accordance with this change effective January 1, 2024. Prior period amounts have been recast to conform to the reporting structure for the current year.


	Year ended December 31, 2024
	United states		Europe		International Markets		Other activities		Total
	(U.S.$ in millions)
Sale of goods		6,327		4,891		2,280		933		14,430
Licensing arrangements		103		35		24		11		173
Distribution		1,536		1		39		—		1,576
Other*		68		176		121		§		365

	$	8,034	$	5,103	$	2,463	$	944	$	16,544

*	“Other” revenues in all segments include revenues related to sales of certain product rights.

§	Represents an amount less than $0.5 million.


	Year ended December 31, 2023
	United states		Europe		International Markets		Other activities		Total
	(U.S.$ in millions)
Sale of goods		5,554		4,631		2,229		565		12,979
Licensing arrangements *		597		51		28		5		681
Distribution		1,577		§		38		—		1,615
Other**		2		155		57		357		570

	$	7,731	$	4,837	$	2,351	$	926	$	15,846

*	Revenues from licensing arrangements in United states segment were mainly comprised of $500 million upfront payment received in connection with the collaboration on Teva’s anti-TL1A asset. See note 2.

**	“Other” revenues in Europe segment mainly related to the sale of certain product rights.

§	Represents an amount less than $0.5 million.


	Year ended December 31, 2022
	United states		Europe		International Markets		Other activities		Total
	(U.S.$ in millions)
Sale of goods		5,383		4,455		2,257		671		12,766
Licensing arrangements		136		51		22		4		212
Distribution		1,471		1		46		—		1,519
Other		13		18		27		370		428

	$	7,003	$	4,525	$	2,352	$	1,045	$	14,925

Summary of Sales Reserves and Allowances


	Sales Reserves and Allowances
	Reserves included in Accounts Receivable, net			Rebates			Medicaid and other governmental allowances			Chargebacks			Returns			Other			Total reserves included in Sales Reserves and Allowances			Total
	(U.S.$ in millions)
Balance at January 1, 2024	$	61			1,603			540			859			436			97		$	3,535		$	3,596
Provisions related to sales made in current year period		390			4,640			787			7,952			276			149			13,804			14,194
Provisions related to sales made in prior periods		—			5			22			(11	)		(22	)		(3	)		(9	)		(9	)
Credits and payments		(395	)		(4,531	)		(781	)		(7,851	)		(286	)		(126	)		(13,575	)		(13,970	)
Translation differences		—			(43	)		(7	)		(13	)		(5	)		(9	)		(77	)		(77	)

Balance at December 31, 2024	$	56		$	1,674		$	561		$	936		$	399		$	108		$	3,678		$	3,734


	Sales Reserves and Allowances
	Reserves included in Accounts Receivable, net			Rebates			Medicaid and other governmental allowances			Chargebacks			Returns			Other			Total reserves included in Sales Reserves and Allowances			Total
	(U.S.$ in millions)
Balance at January 1, 2023	$	67		$	1,575		$	663		$	991		$	455		$	66		$	3,750		$	3,817
Provisions related to sales made in current year period		354			4,015			654			7,579			264			109			12,621			12,975
Provisions related to sales made in prior periods		—			(31	)		(33	)		(54	)		17			—			(101	)		(101	)
Credits and payments		(360	)		(3,974	)		(748	)		(7,662	)		(304	)		(77	)		(12,765	)		(13,125	)
Translation differences		—			18			4			5			4			(1	)		30			30

Balance at December 31, 2023	$	61		$	1,603		$	540		$	859		$	436		$	97		$	3,535		$	3,596